

May 4, 2012

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co (through holdings in Baillie Gifford & Co, and through its wholly owned subsidiary, Baillie Gifford Overseas Limited) has increased its holding of B shares in Novozymes A/S to a total of 25,388,300 B shares of a nominal value of DKK 50,776,600, equivalent to 7.81% of Novozymes A/S' share capital and 3.14% of the voting rights.

Contact persons:

Press and media:

René Tronborg (Europe) Tel. (direct): +45 4446 2274 Tel. (mobile): +45 3077 2274

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209 Tel. (mobile): +1 919 218 4501 Investor relations:

Martin Riise

Tel. (direct): +45 4446 0738 Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483 Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.